Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, noviembre 05
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Rani Therapeutics Holdings Inc
RANI
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$0.5728
0.017
3.06%
Últ. Act.: Nov 4, 7:18 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Rani Therapeutics Hldgs Financials
Rani Therapeutics Hldgs (RANI) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Rani Therapeutics Hldgs Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.708M Beat $925.000K Estimate
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 77.78 percent increase over losses of $(0.18) per share
Benzinga Newsdesk
PRO
Rani Therapeutics Hldgs Q1 EPS $(0.04), Inline, Sales $1.708M Beat $500.000K Estimate
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 81.82 percent increase over losses of $(0.22) per share from the same period last
Benzinga Newsdesk
PRO
Rani Therapeutics Hldgs Q4 EPS $(0.07) Misses $(0.06) Estimate, Sales $1.461M Miss $5.000M Estimate
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 22.81 percent. This is a 74.07 percent increase over losses of $(0.27) per
Benzinga Newsdesk
Earnings Scheduled For March 26, 2026
Benzinga Insights
PRO
Rani Therapeutics Hldgs Q3 EPS $(0.12) Beats $(0.15) Estimate
Cash, cash equivalents and marketable securities as of September 30, 2025 totaled $4.1 million, compared to $27.6 million for the year ended December 31, 2024. Rani expects its cash, and cash equivalents, including the
Benzinga Newsdesk
Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings
Avi Kapoor
